[ChatGPT and the German board examination for ophthalmology: an evaluation]. / ChatGPT und die deutsche Facharztprüfung für Augenheilkunde: eine Evaluierung.

PURPOSE: In recent years artificial intelligence (AI), as a new segment of computer science, has also become increasingly more important in medicine. The aim of this project was to investigate whether the current version of ChatGPT (ChatGPT 4.0) is able to answer open questions that could be asked in the context of a German board examination in ophthalmology. METHODS: After excluding image-based questions, 10 questions from 15 different chapters/topics were selected from the textbook 1000 questions in ophthalmology (1000 Fragen Augenheilkunde 2nd edition, 2014). ChatGPT was instructed by means of a so-called prompt to assume the role of a board certified ophthalmologist and to concentrate on the essentials when answering. A human expert with considerable expertise in the respective topic, evaluated the answers regarding their correctness, relevance and internal coherence. Additionally, the overall performance was rated by school grades and assessed whether the answers would have been sufficient to pass the ophthalmology board examination. RESULTS: The ChatGPT would have passed the board examination in 12 out of 15 topics. The overall performance, however, was limited with only 53.3% completely correct answers. While the correctness of the results in the different topics was highly variable (uveitis and lens/cataract 100%; optics and refraction 20%), the answers always had a high thematic fit (70%) and internal coherence (71%). CONCLUSION: The fact that ChatGPT 4.0 would have passed the specialist examination in 12 out of 15 topics is remarkable considering the fact that this AI was not specifically trained for medical questions; however, there is a considerable performance variability between the topics, with some serious shortcomings that currently rule out its safe use in clinical practice.

Measurements regarding a combined therapy concept for ophthalmic tumors consisting of brachytherapy and x-rays.

Objective.We present a novel concept to treat ophthalmic tumors which combines brachytherapy and low-energy x-ray therapy. Brachytherapy with106Ru applicators is inadequate for intraocular tumors with a height of 7 mm or more. This results from a steep dose gradient, and it is unfeasible to deliver the required dose at the tumor apex without exceeding the maximum tolerable sclera dose of usually 1000 Gy to 1500 Gy. Other modalities, such as irradiation with charged particles, may be individually contraindicated. A dose boost at the apex provided by a superficial x-ray therapy unit, performed simultaneously with the brachytherapy, results in a more homogeneous dose profile than brachytherapy alone. This avoids damage to organs at risk. The applicator may also serve as a beam stop for x-rays passing through the target volume, which reduces healthy tissue dosage. This study aims to investigate the suitability of the applicator to serve as a beam stop for the x-rays.Approach.A phantom with three detector types comprising a soft x-ray ionization chamber, radiochromic films, and a self-made scintillation detector was constructed to perform dosimetry. Measurements were performed using a conventional x-ray unit for superficial therapy to investigate the uncertainties of the phantom and the ability of the applicator to absorb x-rays. The manufacturer provided a dummy plaque to obtain x-ray dose profiles without noise from106Ru decays.Results.The phantom is generally feasible to obtain dose profiles with three different detector types. The interaction of x-rays with the silver of the applicator leads to an increased dose rate in front of the applicator. The dose rate of the x-rays is reduced by up to 90% behind a106Ru applicator. Therefore, a106Ru applicator can be used as a beam stop in combined x-ray and brachytherapy treatment.

[Retinoblastoma]. / Retinoblastom.

Retinoblastomas represent 6% of all malignant tumors in children under 5 years old, which untreated lead to blindness in the affected eye and death due to metastases. The main symptoms are leukocoria and strabismus, which if possible, always necessitate a clarification within 1 week for exclusion of a retinoblastoma. The most frequent differential diagnoses are Coats' disease and persistent fetal vasculature (PFV) as well as other intraocular tumors, in particular astrocytomas. Systemic chemotherapy, if necessary in combination with laser hyperthermia, local chemotherapy and brachytherapy are the most important methods for eye-preserving treatment. Advanced cases mostly necessitate enucleation.

[Multimodal diagnostic of CSNB1 with NYX gene mutation]. / Stufendiagnostik einer CSNB1 mit NYX-Genmutation.

This article presents the case of a young male patient with complete congenital stationary night blindness (CSNB1). The informative value of the general medical history and clinical findings for the diagnosis was impaired due to language barriers and low compliance. Full-field electroretinography and optical coherence tomography help to define particular hereditary retinal dystrophies. Molecular genetic analysis by next generation sequencing as a part of multimodal diagnostics finally uncovered a rare, causal missense mutation in the nyctalopin (NYX) gene.

[Rhegmatogenous retinal detachment : Epidemiology and risk factors]. / Rhegmatogene Netzhautablösung : Epidemiologie und Risikofaktoren.

The incidence of rhegmatogenous retinal detachment in the European population is approximately 10 cases per 100,000 inhabitants per year and reaches a peak in the 6th and 7th decades of life, mostly in atemporal association with posterior vitreous body detachment. Known risk factors include myopia and higher axial length of the eye, male gender, previous trauma and vitreoretinal degeneration or dystrophy. In recent years, an increase in the risk of rhegmatogenous retinal detachment following cataract surgery was also found, especially after capsule rupture and vitreous body loss. In contrast to clear lens extraction (CLE), the refractive intervention of laser in situ keratomileusis (LASIK) does not seem to increase the risk of rhegmatogenous retinal detachment. Retinal detachment stabilizes during physical protection and posturing but progresses through bodily activity and during interruptions in patients with macula-on retinal detachment.

[Short Review of the History of Radiotherapy for Intraocular Tumours]. / Kurzer historischer Rückblick der Strahlentherapie intraokularer Tumoren.

For many decades, radiotherapy with its different modalities has proved to be the gold standard in the treatment of benign and malignant intraocular tumours. The various complicated therapeutic developments in this field cover a period of over 100 years and the present year deserves special mention because of the 100th anniversary of the first mention of a successful brachytherapy for a uveal melanoma by R. Deutschmann in Hamburg in 1915.

[Comparison of IOL-Master 500 vs. Lenstar LS900 concerning the calculation of target refraction: A retrospective analysis]. / Vergleich IOL-Master 500 vs. Lenstar LS900 hinsichtlich der Berechnung der Zielrefraktion: Eine retrospektive Analyse.

BACKGROUND: The choice of a suitable intraocular lens (IOL) and the calculation of postoperative refractive error is one of the most intriguing challenges of modern cataract surgery. This clinical trial compared the accuracy of two laser-assisted optical biometers, the IOL-Master 500 (Carl Zeiss Meditec, Jena, Germany) and the Lenstar LS900 (Haag-Streit, Bern, Switzerland) without taking the postoperative results into consideration. MATERIAL AND METHODS: Artificial lenses (Alcon Pharma) for 114 eyes of 67 patients were measured using both biometric instruments. The deviation of the presumed refractive error from the desired preoperative refractive target was calculated with different formulae (i.e. SRK/T, HofferQ, Haigis and SRKII) based on the intraoperatively chosen IOL. The differences between both instruments were compared using Student's t-test. RESULTS: Using the SRKII formula a mean difference between the IOL-Master and the Lenstar of 0.07 D (p = 0.002) was calculated for 95 eyes, SRK/T used on 47 eyes showed a difference of 0.04 D (p = 0.27), HofferQ measured 0.09 D (p = 0.0001) between both instruments for 88 eyes and the Haigis formula also showed a mean difference of 0.09 D (p = 0.001) based on the calculations of 106 eyes. CONCLUSION: Both instruments gave reproducible and accurate results with only a small deviation from the desired target refraction and can therefore be considered as comparable for the calculation of IOLs. Statistically significant differences in the results were found when using the SRKII, HofferQ and Haigis formulae but these were too low to have any influence on the choice of IOL to be implanted.

In vivo confocal microscopic characterisation of the cornea in chronic graft-versus-host disease related severe dry eye disease.

AIMS: To first describe in vivo confocal microscopic (IVCM) corneal findings in severe dry eye syndrome due to ocular chronic graft versus host disease (cGvHD) after allogeneic stem cell transplantation. METHODS: IVCM of the central cornea was performed in 12 prospectively recruited patients with severe ocular cGvHD associated dry eye syndrome and in six control patients with haematological malignancies without cGvHD. Within each examined corneal layer, at least three non-overlapping areas were selected for representative analysis. RESULTS: The number of sub basal nerve branches was markedly reduced in patients with cGvHD. Sub basal nerve morphology was characterised by increased tortuosity and reduced reflectivity. Accumulation of hyper-reflective extracellular matrix, significantly increased haze and increased keratocyte density were found in the anterior stroma of the study group. CONCLUSIONS: IVCM findings of the cornea in patients with severe ocular cGvHD include a rarefaction of the sub basal corneal nerve plexus and dense accumulation of hyper-reflective extracellular matrix in the anterior stroma.

[Intraocular manifestations of systemic neoplasms]. / Intraokulare Manifestationen bei systemischen Tumorerkrankungen.

There are multiple possible intraocular manifestations in patients with systemic neoplasms. At first line there are uveal, retinal and vitreous metastases from carcinomas, melanomas and lymphomas. In patients with von Hippel Lindau syndrome or familiar adenomatous polyposis coli (FAP), Gardner or Turcot syndromes, fundus examinations can help in the primary diagnosis and thereby facilitate the early detection of systemic neoplasms such as cerebral and spinal haemangioblastoma, kidney or bowel cancer. Furthermore there are rare ocular paraneoplastic syndromes such as the cancer- or melanoma-associated retinopathies (CAR/MAR), the paraneoplastic optic neuropathy (PON) and the bilateral diffuse melanocytic proliferation (BDUMP) that develop secondary to systemic malignancies and can be the primary manifestation.

Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.

OBJECTIVE: Uveal melanoma primarily metastasizes hematogenously with metastases often confined to the liver. The aim of this study was to investigate the presence of circulating tumor cells (CTC) in patients with metastatic disease as a marker for systemic disease and to determine their prognostic relevance. METHODS: Blood samples from 68 patients were collected at the time of initial treatment of metastases. mRNA expression of tyrosinase and MelanA/MART1 as a surrogate marker for the presence of CTC was analyzed by real-time RT-PCR and compared with patient characteristics. RESULTS: CTC were detected in 63% of all patients and in 67% of the 48 patients with only liver metastases. Univariate and multivariate analyses revealed PCR results and serum lactate dehydrogenase as independent prognostic factors for progression-free (hazard ratios 2.2/3.5) and overall survival (hazard ratios 4.0/6.5). Combination of PCR and lactate dehydrogenase divided the patient cohort into 3 groups with distinct prognosis. CONCLUSION: CTC as evidence for systemic disease can be found in the majority of patients with metastatic uveal melanoma, including patients with visible disease confined to the liver. Detection of CTC-specific mRNA transcripts for tyrosinase and MelanA/MART1 by PCR is a poor prognostic factor for progression-free and overall survival. Characterization of CTC could improve the understanding of their biology.